1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Overview 1.1 Product Overview and Scope of NASH (Non-alcoholic Steatohepatitis) Biomarkers 1.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Segment by Type 1.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Value Comparison by Type (2023-2029) 1.2.2 Serum Biomarkers 1.2.3 Hepatic Fibrosis Biomarkers 1.2.4 Apoptosis Biomarkers 1.2.5 Oxidative Stress Biomarkers 1.2.6 Others 1.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Segment by Application 1.3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Value by Application: (2023-2029) 1.3.2 Pharma & CRO Industry 1.3.3 Hospitals 1.3.4 Diagnostic Labs 1.3.5 Academic Research Institutes 1.4 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Estimates and Forecasts 1.4.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue 2018-2029 1.4.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales 2018-2029 1.4.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Average Price (2018-2029) 1.5 Assumptions and Limitations 2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Competition by Manufacturers 2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Manufacturers (2018-2023) 2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Manufacturers (2018-2023) 2.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Average Price by Manufacturers (2018-2023) 2.4 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry Ranking 2021 VS 2022 VS 2023 2.5 Global Key Manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers, Manufacturing Sites & Headquarters 2.6 Global Key Manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers, Product Type & Application 2.7 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Competitive Situation and Trends 2.7.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Concentration Rate 2.7.2 The Global Top 5 and Top 10 Largest NASH (Non-alcoholic Steatohepatitis) Biomarkers Players Market Share by Revenue 2.7.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.8 Manufacturers Mergers & Acquisitions, Expansion Plans 3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Retrospective Market Scenario by Region 3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Region: 2018 Versus 2022 Versus 2029 3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region: 2018-2029 3.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region: 2018-2023 3.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region: 2024-2029 3.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region: 2018-2029 3.3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region: 2018-2023 3.3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region: 2024-2029 3.4 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Facts & Figures by Country 3.4.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country: 2018 VS 2022 VS 2029 3.4.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2029) 3.4.3 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2029) 3.4.4 U.S. 3.4.5 Canada 3.5 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Facts & Figures by Country 3.5.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country: 2018 VS 2022 VS 2029 3.5.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2029) 3.5.3 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2029) 3.5.4 Germany 3.5.5 France 3.5.6 U.K. 3.5.7 Italy 3.5.8 Russia 3.6 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Facts & Figures by Country 3.6.1 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country: 2018 VS 2022 VS 2029 3.6.2 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2029) 3.6.3 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2029) 3.6.4 China 3.6.5 Japan 3.6.6 South Korea 3.6.7 India 3.6.8 Australia 3.6.9 Taiwan 3.6.10 Indonesia 3.6.11 Thailand 3.6.12 Malaysia 3.6.13 Philippines 3.7 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Facts & Figures by Country 3.7.1 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country: 2018 VS 2022 VS 2029 3.7.2 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2029) 3.7.3 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2029) 3.7.4 Mexico 3.7.5 Brazil 3.7.6 Argentina 3.8 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Facts & Figures by Country 3.8.1 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country: 2018 VS 2022 VS 2029 3.8.2 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2029) 3.8.3 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2029) 3.8.4 Turkey 3.8.5 Saudi Arabia 3.8.6 UAE 4 Segment by Type 4.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2029) 4.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2023) 4.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2024-2029) 4.1.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2029) 4.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2018-2029) 4.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2018-2023) 4.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2024-2029) 4.2.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2018-2029) 4.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Type (2018-2029) 5 Segment by Application 5.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2029) 5.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2023) 5.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2024-2029) 5.1.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2018-2029) 5.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2018-2029) 5.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2018-2023) 5.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2024-2029) 5.2.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2018-2029) 5.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Application (2018-2029) 6 Key Companies Profiled 6.1 GENFIT SA 6.1.1 GENFIT SA Corporation Information 6.1.2 GENFIT SA Description and Business Overview 6.1.3 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023) 6.1.4 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio 6.1.5 GENFIT SA Recent Developments/Updates 6.2 Gilead Sciences, Inc. (GILD) 6.2.1 Gilead Sciences, Inc. (GILD) Corporation Information 6.2.2 Gilead Sciences, Inc. (GILD) Description and Business Overview 6.2.3 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023) 6.2.4 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio 6.2.5 Gilead Sciences, Inc. (GILD) Recent Developments/Updates 6.3 AstraZeneca 6.3.1 AstraZeneca Corporation Information 6.3.2 AstraZeneca Description and Business Overview 6.3.3 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023) 6.3.4 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio 6.3.5 AstraZeneca Recent Developments/Updates 6.4 Novartis AG 6.4.1 Novartis AG Corporation Information 6.4.2 Novartis AG Description and Business Overview 6.4.3 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023) 6.4.4 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio 6.4.5 Novartis AG Recent Developments/Updates 6.5 Bristol-Myers Squibb Company 6.5.1 Bristol-Myers Squibb Company Corporation Information 6.5.2 Bristol-Myers Squibb Company Description and Business Overview 6.5.3 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023) 6.5.4 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio 6.5.5 Bristol-Myers Squibb Company Recent Developments/Updates 6.6 Allergan Plc 6.6.1 Allergan Plc Corporation Information 6.6.2 Allergan Plc Description and Business Overview 6.6.3 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023) 6.6.4 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio 6.6.5 Allergan Plc Recent Developments/Updates 6.7 Novo Nordisk A/S 6.6.1 Novo Nordisk A/S Corporation Information 6.6.2 Novo Nordisk A/S Description and Business Overview 6.6.3 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023) 6.4.4 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio 6.7.5 Novo Nordisk A/S Recent Developments/Updates 6.8 Boehringer Ingelheim 6.8.1 Boehringer Ingelheim Corporation Information 6.8.2 Boehringer Ingelheim Description and Business Overview 6.8.3 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023) 6.8.4 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio 6.8.5 Boehringer Ingelheim Recent Developments/Updates 6.9 Pfizer Inc 6.9.1 Pfizer Inc Corporation Information 6.9.2 Pfizer Inc Description and Business Overview 6.9.3 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023) 6.9.4 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolio 6.9.5 Pfizer Inc Recent Developments/Updates 7 Industry Chain and Sales Channels Analysis 7.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry Chain Analysis 7.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Key Raw Materials 7.2.1 Key Raw Materials 7.2.2 Raw Materials Key Suppliers 7.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Mode & Process 7.4 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales and Marketing 7.4.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Channels 7.4.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors 7.5 NASH (Non-alcoholic Steatohepatitis) Biomarkers Customers 8 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Dynamics 8.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry Trends 8.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Drivers 8.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Challenges 8.4 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Restraints 9 Research Finding and Conclusion 10 Methodology and Data Source 10.1 Methodology/Research Approach 10.1.1 Research Programs/Design 10.1.2 Market Size Estimation 10.1.3 Market Breakdown and Data Triangulation 10.2 Data Source 10.2.1 Secondary Sources 10.2.2 Primary Sources 10.3 Author List 10.4 Disclaimer

List of Tables Table 1. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Value Comparison by Type (2023-2029) & (US$ Million) Table 2. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Value Comparison by Application (2023-2029) & (US$ Million) Table 3. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Competitive Situation by Manufacturers in 2022 Table 4. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units) of Key Manufacturers (2018-2023) Table 5. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Manufacturers (2018-2023) Table 6. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (US$ Million) by Manufacturers (2018-2023) Table 7. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Share by Manufacturers (2018-2023) Table 8. Global Market NASH (Non-alcoholic Steatohepatitis) Biomarkers Average Price (USD/Unit) of Key Manufacturers (2018-2023) Table 9. Global Key Players of NASH (Non-alcoholic Steatohepatitis) Biomarkers, Industry Ranking, 2021 VS 2022 VS 2023 Table 10. Global Key Manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers, Manufacturing Sites & Headquarters Table 11. Global Key Manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers, Product Type & Application Table 12. Global Key Manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers, Date of Enter into This Industry Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 14. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NASH (Non-alcoholic Steatohepatitis) Biomarkers as of 2022) Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans Table 16. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Table 17. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2018-2023) & (K Units) Table 18. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2018-2023) Table 19. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2024-2029) & (K Units) Table 20. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2024-2029) Table 21. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2018-2023) & (US$ Million) Table 22. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region (2018-2023) Table 23. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2024-2029) & (US$ Million) Table 24. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region (2024-2029) Table 25. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 26. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023) & (K Units) Table 27. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2024-2029) & (K Units) Table 28. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023) & (US$ Million) Table 29. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2024-2029) & (US$ Million) Table 30. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 31. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023) & (K Units) Table 32. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2024-2029) & (K Units) Table 33. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023) & (US$ Million) Table 34. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2024-2029) & (US$ Million) Table 35. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million) Table 36. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2018-2023) & (K Units) Table 37. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2024-2029) & (K Units) Table 38. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2018-2023) & (US$ Million) Table 39. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2024-2029) & (US$ Million) Table 40. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 41. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023) & (K Units) Table 42. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2024-2029) & (K Units) Table 43. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023) & (US$ Million) Table 44. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2024-2029) & (US$ Million) Table 45. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 46. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023) & (K Units) Table 47. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2024-2029) & (K Units) Table 48. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023) & (US$ Million) Table 49. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2024-2029) & (US$ Million) Table 50. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units) by Type (2018-2023) Table 51. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units) by Type (2024-2029) Table 52. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023) Table 53. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2024-2029) Table 54. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (US$ Million) by Type (2018-2023) Table 55. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (US$ Million) by Type (2024-2029) Table 56. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2018-2023) Table 57. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2024-2029) Table 58. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price (USD/Unit) by Type (2018-2023) Table 59. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price (USD/Unit) by Type (2024-2029) Table 60. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units) by Application (2018-2023) Table 61. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units) by Application (2024-2029) Table 62. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2018-2023) Table 63. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2024-2029) Table 64. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (US$ Million) by Application (2018-2023) Table 65. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (US$ Million) by Application (2024-2029) Table 66. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2018-2023) Table 67. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2024-2029) Table 68. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price (USD/Unit) by Application (2018-2023) Table 69. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price (USD/Unit) by Application (2024-2029) Table 70. GENFIT SA Corporation Information Table 71. GENFIT SA Description and Business Overview Table 72. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 73. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Table 74. GENFIT SA Recent Developments/Updates Table 75. Gilead Sciences, Inc. (GILD) Corporation Information Table 76. Gilead Sciences, Inc. (GILD) Description and Business Overview Table 77. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 78. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Table 79. Gilead Sciences, Inc. (GILD) Recent Developments/Updates Table 80. AstraZeneca Corporation Information Table 81. AstraZeneca Description and Business Overview Table 82. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 83. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Table 84. AstraZeneca Recent Developments/Updates Table 85. Novartis AG Corporation Information Table 86. Novartis AG Description and Business Overview Table 87. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 88. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Table 89. Novartis AG Recent Developments/Updates Table 90. Bristol-Myers Squibb Company Corporation Information Table 91. Bristol-Myers Squibb Company Description and Business Overview Table 92. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 93. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Table 94. Bristol-Myers Squibb Company Recent Developments/Updates Table 95. Allergan Plc Corporation Information Table 96. Allergan Plc Description and Business Overview Table 97. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 98. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Table 99. Allergan Plc Recent Developments/Updates Table 100. Novo Nordisk A/S Corporation Information Table 101. Novo Nordisk A/S Description and Business Overview Table 102. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 103. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Table 104. Novo Nordisk A/S Recent Developments/Updates Table 105. Boehringer Ingelheim Corporation Information Table 106. Boehringer Ingelheim Description and Business Overview Table 107. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 108. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Table 109. Boehringer Ingelheim Recent Developments/Updates Table 110. Pfizer Inc Corporation Information Table 111. Pfizer Inc Description and Business Overview Table 112. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 113. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Table 114. Pfizer Inc Recent Developments/Updates Table 115. Key Raw Materials Lists Table 116. Raw Materials Key Suppliers Lists Table 117. NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors List Table 118. NASH (Non-alcoholic Steatohepatitis) Biomarkers Customers List Table 119. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Trends Table 120. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Drivers Table 121. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Challenges Table 122. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Restraints Table 123. Research Programs/Design for This Report Table 124. Key Data Information from Secondary Sources Table 125. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of NASH (Non-alcoholic Steatohepatitis) Biomarkers Figure 2. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Value Comparison by Type (2023-2029) & (US$ Million) Figure 3. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share by Type in 2022 & 2029 Figure 4. Serum Biomarkers Product Picture Figure 5. Hepatic Fibrosis Biomarkers Product Picture Figure 6. Apoptosis Biomarkers Product Picture Figure 7. Oxidative Stress Biomarkers Product Picture Figure 8. Others Product Picture Figure 9. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Value Comparison by Application (2023-2029) & (US$ Million) Figure 10. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share by Application in 2022 & 2029 Figure 11. Pharma & CRO Industry Figure 12. Hospitals Figure 13. Diagnostic Labs Figure 14. Academic Research Institutes Figure 15. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue, (US$ Million), 2018 VS 2022 VS 2029 Figure 16. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size (2018-2029) & (US$ Million) Figure 17. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (2018-2029) & (K Units) Figure 18. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Average Price (USD/Unit) & (2018-2029) Figure 19. NASH (Non-alcoholic Steatohepatitis) Biomarkers Report Years Considered Figure 20. NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Share by Manufacturers in 2022 Figure 21. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Share by Manufacturers in 2022 Figure 22. The Global 5 and 10 Largest NASH (Non-alcoholic Steatohepatitis) Biomarkers Players: Market Share by Revenue in 2022 Figure 23. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022 Figure 24. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Figure 25. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2018-2029) Figure 26. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2018-2029) Figure 27. U.S. NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 28. Canada NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 29. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2018-2029) Figure 30. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2018-2029) Figure 31. Germany NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 32. France NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 33. U.K. NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 34. Italy NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 35. Russia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 36. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2018-2029) Figure 37. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region (2018-2029) Figure 38. China NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 39. Japan NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 40. South Korea NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 41. India NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 42. Australia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 43. Taiwan NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 44. Indonesia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 45. Thailand NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 46. Malaysia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 47. Philippines NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 48. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2018-2029) Figure 49. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2018-2029) Figure 50. Mexico NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 51. Brazil NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 52. Argentina NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 53. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2018-2029) Figure 54. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2018-2029) Figure 55. Turkey NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 56. Saudi Arabia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 57. UAE NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate (2018-2029) & (US$ Million) Figure 58. Global Sales Market Share of NASH (Non-alcoholic Steatohepatitis) Biomarkers by Type (2018-2029) Figure 59. Global Revenue Market Share of NASH (Non-alcoholic Steatohepatitis) Biomarkers by Type (2018-2029) Figure 60. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price (USD/Unit) by Type (2018-2029) Figure 61. Global Sales Market Share of NASH (Non-alcoholic Steatohepatitis) Biomarkers by Application (2018-2029) Figure 62. Global Revenue Market Share of NASH (Non-alcoholic Steatohepatitis) Biomarkers by Application (2018-2029) Figure 63. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price (USD/Unit) by Application (2018-2029) Figure 64. NASH (Non-alcoholic Steatohepatitis) Biomarkers Value Chain Figure 65. NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Process Figure 66. Channels of Distribution (Direct Vs Distribution) Figure 67. Distributors Profiles Figure 68. Bottom-up and Top-down Approaches for This Report Figure 69. Data Triangulation Figure 70. Key Executives Interviewed

GENFIT SA Gilead Sciences, Inc. (GILD) AstraZeneca Novartis AG Bristol-Myers Squibb Company Allergan Plc Novo Nordisk A/S Boehringer Ingelheim Pfizer Inc